Unique among ‘Person of the Year’ designees, Donald Trump gets a fact-check from Time magazinedownload phlboss 。

BLOOMINGTON — November is National Novel Writing Month. The official website, NaNoWriMo.org , challenges writers to write 50,000 words in the 30-day month, for either a new novel or for a literary work that’s already in progress. By the numbers, a draft of that length roughly types out at 1,612 words every day. To even a modestly wordy columnist like myself, that can seem like a lot. One piece of advice that often bears repeating is that writers literally just need to start writing, and to stop getting hung up on writing the first sentence perfectly from the start. I know I've needed to hear that. That point was also echoed in an interview with a self-published author in Normal who's taken this month's writing challenge seven times before. She was among other area authors who dialed in or sat down for interviews with me to provide writing tips for National Novel Writing Month. All below authors also attended a Local Author Fair event hosted Nov. 9 at the Bloomington Public Library. Shown with her cat Biscuit is Sue Rovens. 'In A Corner, Darkly' Sue Rovens said she has participated in National Novel Writing Month seven times. She has also published seven pieces of writing: five novels and two collections of short stories. The 60-year-old Normal resident said writing is a solitary activity for herself, and most other people. The NaNoWriMo organization, however, can connect writers with online communities, like coffee chat rooms, Rovens said, adding that groups can be created be for writers who are 50 and older, or who write certain genres, like science fiction and horror. What drew her to the NaNoWriMo organization, Rovens said, is, “I saw that there isn’t really any winners or losers.” She said the 50,000 words written in a month could go into a novel, screenplay or poetry. “It can be anything you want it to be,” said Rovens. “it’s just an avenue for people who want to be aspiring writers and professional writers to kind of join together in the month of November and create something.” She said she’s used it for first drafts of her novels, and to complete them in 30 days. And, it helped her keep a word count. Rovens said she didn’t participate in in NaNoWriMo this year because she is working on a manuscript for the third volume of her series, “In A Corner, Darkly,” and plans to release it next year. She said it’s a collection of 15 short stories that run the gamut from old-school horror to apocalyptic themes, plus some sci-fi speculation. Rovens said she published her first book in 2012, and has been writing since 2009. “I’m no Stephen King, but I’ve been doing it a while," she said. Rovens’ appreciation for King, and Jack Ketchum, is demonstrated in the short story “Funeral Games” in the second volume of “In A Corner, Darkly.” It concludes with a digestible fright, before the volume turns toward even darker corners of thought in later stories. When asked to share writing tips, Rovens said she always runs into other writers who’ve told her, “I can’t ever get past the first paragraph,” because they keep editing it. She said you must write the first draft. You’ll make all kinds of mistakes, but that’s OK — she said to let that first draft exist. “If you’re never happy with those first few sentences, you’ll never get farther than that first page,” she said. Rovens’ series “In A Corner, Darkly” is available at Bobzbay Books in downtown Bloomington, and via Amazon. Feinman Ink & Feather Comics Anthony Feinman, of Bloomington, said in order to independently publish his works as a cartoonist, he has “do it all.” He said he takes on tasks including writing, illustration, pagination and more for the comic book series named “ASININE.” Feinman co-created and co-writes the series with his wife, Julia Simack , a fine artist who specializes in oil painting . It’s published by Ink & Feathers Comics , where Feinman serves an art director . Feinman said the third issue of "ASININE" is planned for release in late 2025. He also said he’s working on republishing his father’s sci-fi novel, “Teddy Bear Conspiracy.” Another comic Feinman illustrated and co-authored with Andrew Hall is “Blitz Howser: The Lost Strips,” which was first introduced as a webcomic and has a namesake character similar to Zap Brannigan from the “Futurama” TV series. He said "Blitz Howser" will also be rereleased. Feinman said he’s published webcomics on and off over the years. He noted that three or four comic panels is a limited amount of space to tell a story in, and that the style of prose used in comics is closer to scriptwriting, when compared to novel writing. Feinman said the second issue of “ASININE” satirizes the comic book industry and is inspired by personal experiences attending comic book conventions, with a little exaggeration. He said comics have long been considered as media for children, but cartoonists consider themselves artists, too. Feinman said “Calvin & Hobbes” creator Bill Watterson wanted to change how people view comic art, and he pushed the envelope with his work. In the modern, digital age, Feinman said it’s hard to find your voice, and selling books is now more cumbersome. In the 1990s, he said, books sold more easily; now, authors have to compete more for readers' attention. “So many people are expressing themselves, which is absolutely wonderful that people are able to get their stuff out there,” said Feinman. He said there are still active readers, but they’re also into television, video games and other media. His best advice, Feinman said, is if you’ve got something in your head, “get that out first.” He said there are many ideas going though his head, and it’s a matter of working on them one at a time. “Do what you’re passionate about, and then everything else will come afterward,” he said. He also said it’s fun to go to events like the author fair at BPL, where he can encounter other creators. “You don’t know if the person next door is someone who’s written a novel you may fall in love with,” he said. Direct ordering of Feinman’s comics is available at ifcomics.com ; his comics can also be ordered on Amazon. Lovell 'Catharsis' Rhys Lovell, of Bloomington, said he has no training as a writer. The artistic director at Heartland Theatre Co. said he has written two screenplays and a novel, but acting is his main thing. The screenplays include “Pangaea Fell” and “The Imaginist.” In October 2023, Lovell released a techno-thriller novel, “Catharsis.” It’s also available as an audiobook. The plot of the novel was inspired by his discovery of “rage rooms,” Lovell said, which is a place where people can engage in “destruction therapy.” He said he discovered rage rooms because his younger brother, Thad, was experiencing intermittent explosive disorder, and he didn’t know how to help him. Lovell said he has a close relationship with his brother, who is in a much better place today. For his novel, Lovell, 59, said he imagined what a rage room would look like if technology were more sophisticated. “Instead of paying $50 bucks and they give you a baseball bat, (and) you go in a room and you bust up old computer parts, what if now you're now facing off against the person at whom your wrath is directed?” asked Lovell. “Catharsis” also dives into themes of cloning and fabricating replicants of people by stealing their DNA. Lovell said in his novel, only wealthy elites can afford the services offered by a company that's also called Catharsis. In this fictional world, the company's customers are offered to kill clones of their choosing — but the replication technology goes awry. He said writing a story that’s set in the future is, in many ways, much easier, because you are doing that world-building and inventing stuff that doesn’t exist. “You can’t really get fact checked on it,” he said. His next novel will be titled “Monstruo,” the Spanish word for monster. The main character, Arturo, is loosely based on the drug lord El Chapo, and readers will understand the abuse Arturo was subjected to as a boy, Lovell said. When world building, Lovell said sometimes that’s imagining a world we haven’t seen yet, like in “Catharsis.” Lovell said writers have suggested to “write what you know,” but on the flip side is the advice, “write what you want to know more about.” “That’s where I’m going with Monstruo,” Lovell said. Lovell said he uses a mobile app called Storybuilder to help plan a developing novel’s characters, locations, scenes and more. He said he thinks of the outline as more of events in a story instead of chapters. He said part of the process, which he borrows from his acting experiences, is to inhabit his characters’ lives and step into their shoes. “I encourage writers to engage all their senses when they write ... regardless of what you’re writing about, see the sights, hear the sounds, smell the smells and make sure your writing is specific,” said Lovell. Lovell and Rovens both said they share their drafts with “beta readers” for consultation. “Don’t cherry pick them in such a way that you know you’re always going to get positive feedback,” Lovell said of beta readers. Lovell plans to release his next novel by fall 2025. To order “Catharsis," visit linktr.ee/rhyslovell or message him at facebook.com/catharsisnovel . The public libraries in Bloomington and Normal organize teen writing workshops. At the Bloomington Public Library, 205 E. Olive St., creative writing workshops for teenagers are scheduled from noon-1 p.m. Dec. 18, Jan. 22 and Feb. 26. The Normal Public Library has scheduled teen writing workshops at The Coffeehouse, 114 E. Beaufort St. in uptown, from 4-5 p.m. Dec. 19 and Jan. 16. Illinois residents can access self-publishing resources at inkie.org . Bloomington Public Library officials cut the ribbon on the newly expanded facility Aug. 1, after 25 months of renovation and construction work. Contact Brendan Denison at (309) 820-3238. Follow Brendan Denison on Twitter: @BrendanDenison Stay up-to-date on what's happening Receive the latest in local entertainment news in your inbox weekly! Breaking News Reporter {{description}} Email notifications are only sent once a day, and only if there are new matching items.ISU men's basketball set to face Ohio StateMuseum exhibitions see growing fan base in China

A woman accused of hosing down her neighbour's house has allegedly assaulted police officers who attended the dispute, one of whom was also bitten by her dog. Subscribe now for unlimited access . Login or signup to continue reading All articles from our website & app The digital version of Today's Paper Breaking news alerts direct to your inbox Interactive Crosswords, Sudoku and Trivia All articles from the other regional websites in your area Continue ACT Policing officers responded to a neighbours' quarrel in Taylor about 3pm on Friday, December 13. There was a resolution, however, police were called to the address again hours later because the woman had allegedly restarted the dispute. "About 7.20pm, police returned to the residences after the woman allegedly breached an undertaking to keep the peace by spraying her neighbour's home with a hose and yelling abuse," a police spokeswoman said. "Officers attempted to speak to the woman but one officer was bitten by her dog when she went inside her residence." An ACT Policing officer. Picture by Karleen Minney Police arrested the 36-year-old woman but she allegedly kicked and injured two officers before they handcuffed her. Once in custody at the ACT Watch House , the woman is again accused of assaulting two different officers. she allegedly bit one of them on the arm and scratched another on the hand. As a result, she was charged with multiple offences, including two counts of assaulting frontline community service providers and two counts of assault occasioning actual bodily harm. The woman is due to appear before the ACT Magistrates Court on Saturday. Share Facebook Twitter Whatsapp Email Copy Bageshri Savyasachi Journalist I am the police reporter for The Canberra Times. I cover crime, corrections and other emergency services. I am interested in investigative journalism and human stories. Contact me at bageshri.s@canberratimes.com.au or send confidential tips to bageshri.s@proton.me I am the police reporter for The Canberra Times. I cover crime, corrections and other emergency services. I am interested in investigative journalism and human stories. Contact me at bageshri.s@canberratimes.com.au or send confidential tips to bageshri.s@proton.me More from Canberra Woman and her dog accused of biting police who attended neighbour dispute 22m ago This childcare overhaul will actually do very little for parents No comment s All you need to know about the nasty stuff in Canberra's waterways No comment s The RSPCA is looking for foster carers over Christmas No comment s Alex thought he was helping, and had approval - until almost the last minute No comment s Like the 'English aristocracy', but in 1940s Canberra No comment s Newsletters & Alerts View all DAILY Your morning news Today's top stories curated by our news team. Also includes evening update. Loading... WEEKDAYS The lunch break Grab a quick bite of today's latest news from around the region and the nation. Loading... DAILY Sport The latest news, results & expert analysis. Loading... WEEKDAYS The evening wrap Catch up on the news of the day and unwind with great reading for your evening. Loading... WEEKLY Note from the Editor Get the editor's insights: what's happening & why it matters. Loading... WEEKLY FootyHQ Love footy? We've got all the action covered. Loading... DAILY Early Look At David Pope Your exclusive preview of David Pope's latest cartoon. Loading... AS IT HAPPENS Public Service News Don't miss updates on news about the Public Service. Loading... WEEKLY Explore Travel Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. Loading... WEEKLY Property Get the latest property and development news here. Loading... WEEKLY What's On Going out or staying in? Find out what's on. Loading... WEEKLY Weekend Reads We've selected the best reading for your weekend. Loading... WEEKLY Times Reader's Panel Join our weekly poll for Canberra Times readers. Loading... WEEKDAYS The Echidna Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. Loading... TWICE WEEKLY The Informer Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. Loading... WEEKLY Motoring Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. Loading... TWICE WEEKLY Voice of Real Australia Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. Loading... AS IT HAPPENS Breaking news alert Be the first to know when news breaks. Loading... DAILY Today's Paper Alert Your digital replica of Today's Paper. Ready to read from 5am! Loading... DAILY Your favourite puzzles Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Loading...Aspen Group Reports Positive Cash from Operations Fiscal Year-to-Date

Lost 'friend, philosopher and guide', says Sonia Gandhi on Manmohan Singh's demise"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.Russell Sage junior defender Courtney Bush (Mohonasen) earned All-Region honors from the United Soccer Coaches for the second straight season. Bush, the anchor of the defense, was voted fourth-team All-Region, as well as second-team All-Empire 8 Conference. Kutztown University freshman RJ Otten (Ballston Spa) set the school record in the men’s 400-yard individual medley on Nov. 23, in 4:11.18, while finishing fourth at the Franklin & Marshall Invitational. He also placed 14th in the 200 butterfly at the event on the next day, in 1:58.50, qualifying him for the Pennsylvania State Athletic Conference Championships. On Dec. 7, he placed second in the 200 backstroke in a dual meet against Arcadia, in 2:02.94, which qualified him for the PSACCs in that event. Sign Up: The Daily Gazette's Rotterdam weekly newsletter in your inbox Two local players for the Utica University football team made the third team of the Empire 8 Conference All-Star Team. Senior offensive lineman Russell Porter (Canajoharie) started all 10 games at left tackle and protected his backfield mates very well. Junior wide receiver Antonio Cianfarani (Scotia-Glenville) was the Pioneers’ leading receiver with 28 catches for 394 yards and three touchdowns. Two local women’s indoor track and field athletes shared Empire 8 Conference Co-Field Athlete of the Week honors on Monday: Houghton freshman Alexa Belanger (Burnt Hills-Ballston Lake) and SUNY Geneseo senior Zoe Connor (Scotia-Glenville). Belanger won the high jump in her first intercollegiate meet Friday at the Houghton December Classic with a height of 1.64 meters (5 feet, 4.5 inches), which is currently sixth in Division III and second all-time in school history. Connor set a program record for the shot put on Friday at Nazareth, winning with a distance of 12.89 meters (42 feet, 3.5 inches). She also won the weight throw with a 16.95 meters (55-7.5), which ranks seventh in Division III. Through Dec. 7, AIC senior power forward Rhaymi Porter (Scotia-Glenville/Wilbraham Monson Academy) had started all eight games and was averaging 4.4 points, 9.6 rebounds and 2.75 blocks for the women’s basketball team. Through Dec. 7, Paul Smith’s junior center Colin Palmer (Shenendehowa) was second in scoring on the men’s hockey team with 31 points, on 10 goals and 21 assists. SUNY Potsdam graduate student captain Kenzie Cerny (Shenendehowa) swam to victory in the women’s 200 butterfly at the North Country Invitational on Nov. 23. Her time was 2:26.49. She also was second in the 400 IM in 5:06.89. In an earlier win over Bard, she won the 1,000 freestyle (11:56.15) and 100 backstroke (1:06.28). Through Dec. 7, SUNY Plattsburgh junior guard Jaden Wilson (Johnstown) was third on the women’s basketball team in scoring with 8.4 points per game. She also averaged 3.7 rebounds per game. Through Dec. 7, Hudson Valley Community College freshman forward Lila Christensen (Mechanicville) averaged 6.7 points and 4.6 rebounds per game for the women’s basketball team. SUNY Oswego junior guard Sydney Hoefs (Amsterdam) averaged 5.8 points, 4.0 rebounds and 3.6 assists for the women’s basketball team through Dec. 7. SUNY Oswego junior Nathan Ratta Vine (Burnt Hills-Ballston Lake) won the 100-yard breaststroke (1:03.48) and 100 individual medley (56.47), and placed second in the 200 freestyle to help the Lakers edge SUNY Brockport in a men’s dual meet, 147-144. On Nov. 23, he placed third in the 200 IM (2:03.54) at the North Country Invite. Suffolk University sophomore guard Nick Verdile (Ballston Spa) went 7 for 9 on 3-pointers and scored a career-high 21 points in the Rams’ 90-42 win over Curry on Saturday.

President Javier Milei has said that the Senate session in which Edgardo Kueider was expelled over corruption allegations was void because his vice, Victoria Villarruel, led the session while acting as president of the nation. Milei traveled to Italy on Thursday, leaving Villarruel as acting president, but she has responded publicly that she was not formally transferred the presidential power until after the session had ended. The episode underscores the increasingly public rift between the president and his second-in-command. “The session is invalid,” Milei said on Friday during an interview with Luis Majul on radio station El Observador. On Thursday, the Upper House voted to expel Senator Edgardo Kueider from Congress after he was arrested in Paraguay with over US$200,000 of undeclared cash while crossing the border from Brazil. Kueider was a Peronist lawmaker, but voted for Milei’s flagship bill, the Ley Bases. Like Milei, his lawyer said the session was null and filed a writ for Kueider to be reinstated. In Argentina, the Vice President is also head of the senate. However, Milei argued that Villarruel should not have presided over the session because he was in Rome and she should have been the acting president, not the head of the Senate. Milei said that, according to current legislation, the vice president “automatically” acts as president if the president travels overseas. That role is then occupied by the provisional spokesperson of the Senate, who is currently Bartolomé Abdala. “If she presides over the session of the Congress, she is working in the Legislative Branch, but at the same time, she is the acting president of the nation [...,] she is occupying two positions, and that violates the separation of powers,” he said. Villarruel responded that the temporary transfer of power did not take effect until it had been formally signed off. “Until the power of attorney [to be President] is transferred to me, I am vice president. And that is done through the presidency’s notary. I signed the minutes giving my consent at 7:00 p.m.,” Villarruel wrote, answering a comment on her Instagram account. Screenshots of what appears to be a chat with Villarruel’s secretary were published by various news websites. They show a conversation timestamped 8:36 a.m. on Tuesday, stating the president’s time of departure and arrival. The secretary responds “OK” to the messages. The chats also show a letter notifying Villarruel of Milei’s trip through the Electronic Document Management System (GDE, by its Spanish acronym), which stores all proceedings and files within the public administration. Milei mentioned the letter in his interview. A spokesperson for Villarruel told the Herald that Villarruel was not aware of the trip, that the Legislative Branch does not use the GDE, and that the vice president does not have a username for the system in the Senate building. Milei’s trip to Italy, although not his departure time, had been reported by media including the Herald over a week before he departed. The relationship between Milei and Villarruel has been strained for months, with the president calling her part of the “caste” and leaving her off the guestlist for government events. She was not present for Milei’s first anniversary speech celebrating one year in power. “I would have loved to be there,” Villarruel wrote in a comment on her Instagram account. Villarruel lamented that Kueider was expelled from the Congress, implying that she does not consider him a member of the Peronist bloc. Since Kueider entered Congress on a Peronist ticket, his seat will now be granted to Stefania Cora, who is associated with Maximo Kirchner’s organization La Cámpora. “We are going to work until our last breath so that the [Kirchners] no longer manage the designs of our country,” Villarruel wrote on X. Meanwhile, Kueider is currently being investigated in Paraguay for attempted smuggling. Peronist senator Oscar Parrilli, social democrat deputy Margarita Stolbizer, and left-wing former deputy Myriam Bregman have suggested that Kueider was smuggling money from a government bribe to vote for the Ley Bases. Investigators have not reached any formal conclusions about the origin of the funds. Bregman’s party, the Party of the Socialist Workers (PTS) demanded that the Ley Bases be declared void. The vote on the controversial bill was tied in Argentina’s senate, with Villarruel casting the deciding vote in favor of the government.Topline Longtime Wall Street favorite Nvidia extended a rare down stretch, as shares of the artificial intelligence colossus slipped into correction territory, a ding that comes as Nvidia’s trillion-dollar peers enjoy a robust period of gains. Key Facts Big Number 5.7%. That’s how much shares of Nvidia are down since Election Day, far underperforming the S&P 500 index’s 5% gain during the period. Notably, the six-week stretch has been a strong one for Nvidia’s big tech peers, as each of the other Magnificent Seven stocks advanced at least 9.9%. There has been no singular catalyst for the Nvidia selloff – its earnings report last month exceeded analyst estimates across the board – though the stock has previously slumped due to geopolitical fears from Nvidia’s reliance on Taiwanese manufacturers. Contra The recent dip for Nvidia shares may be hard to digest for investors, especially in an otherwise rosy market, but the stock’s longer-term returns are still eye popping. Nvidia’s 170% year-to-date return is the best of any company valued at more than $200 billion, according to FactSet data, with shares up a whopping 700% over the last two years. Key Background Nvidia rose to prominence over the last two years as the unquestioned market leader in designing the semiconductor technology powering generative AI, causing its market capitalization to grow from below $300 billion in late 2022 to as high as $3.6 trillion last month. Nvidia, whose clientele includes Amazon and Microsoft, translated the surging interest in generative AI into a significant upswing in its financial performance, as sales grew by more than 600% during Nvidia’s most recent quarter compared to 2022’s comparable period. Nvidia is still the third-largest company in the world by market value, trailing only Apple and Microsoft.

Parliament set to hold an 11th hour vote on $21B in government spendingAustin Public Library: Library an important resource

Trump gave Interior nominee one directive for a half-billion acres of US land: ‘Drill.’NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Scrim, a 17-pound mutt that's mostly terrier, has become a folk hero, inspiring tattoos, T-shirts and even a ballad as he eludes capture from the posse of volunteers. And like any antihero, Scrim has a backstory: Rescued from semi-feral life at a trailer park and adopted from a shelter, the dog broke loose in April and scurried around the city until he was cornered in October and brought to a new home. Weeks later, he'd had enough. Scrim leaped out of a second-story window, a desperate act recorded in a now-viral video. Since then, despite a stream of daily sightings, he's roamed free. The dog’s fans include Myra and Steve Foster, who wrote “Ode to Scrim” to the tune of Ricky Nelson’s 1961 hit, “I’m a Travelin’ Man.” “I'm a travelin' dog and I've made a lot of stops/All over this town...” Leading the recapture effort is Michelle Cheramie, a 55-year-old former information technology professional. She lost everything — home, car, possessions — in Hurricane Katrina in 2005, and in the aftermath, found her calling rescuing pets. “I was like, ‘This is what I should be doing,’” Cheramie said. “I was born to rescue.” She launched Zeus’ Rescues, a nonprofit shelter that now averages 600 cat and dog adoptions a year and offers free pet food to anyone who needs it. She helped Scrim find the home he first escaped from. It was Cheramie's window Scrim leaped from in November. She's resumed her relentless mission since then, posting flyers on telephone poles and logging social media updates on his reported whereabouts. She's invested thousands of dollars on wildlife cameras, thermal sensors and other gear. She took a course offered by the San Diego Zoo on the finer points of tranquilizing animals. And she's developed a network of volunteers — the kind of neighbors who are willing to grid-search a city at 3 a.m. “...And at every stop I own the heart, of at least one lovely ... " People like writer David W. Brown, who manages a crowd-sourced Google Map of all known Scrim sightings. He says the search has galvanized residents from all walks of life to come together. As they search for Scrim, they hand out supplies to people in need. “Being a member of the community is seeing problems and doing what you can to make life a little better for the people around here and the animals around you,” Brown said. And neighbors like Tammy Murray, who had to close her furniture store and lost her father to Parkinson's disease. This search, she says, got her mojo back. “Literally, for months, I’ve done nothing but hunt this dog,” said Murray, 53. “I feel like Wile E. Coyote on a daily basis with him.” Murray drives the Zeus' Rescues' van towards reported Scrim sightings. She also handles a tactical net launcher, which looks like an oversized flashlight and once misfired, shattering the van's window as Scrim sped away. After realizing Scrim had come to recognize the sound of the van's diesel engine, Murray switched to a Vespa scooter, for stealth. “...If you're ever in the 9th Ward stop and see/My cute little mini poodle ...” Near-misses have been tantalizing. The search party spotted Scrim napping beneath an elevated house, and wrapped construction netting around the perimeter, but an over-eager volunteer broke ranks and dashed forward, leaving an opening Scrim slipped through. Scrim's repeated escapades have prompted near-daily local media coverage and a devoted online following. Cheramie can relate. “We’re all running from something or to something. He's doing that too,” she said. Cheramie's team dreams of placing the pooch in a safe and loving environment. But a social media chorus growing under the hashtag #FreeScrim has other ideas — they say the runaway should be allowed a life of self-determination. The animal rescue volunteers consider that misguided. “The streets of New Orleans are not the place for a dog to be free,” Cheramie said. “It’s too dangerous.” "... and my Shar-Pei doll down in old Treme/Waits for my return ..." Scrim was a mess when Cheramie briefly recaptured him in October, with matted fur, missing teeth and a tattered ear. His trembling body was scraped and bruised, and punctured by multiple projectiles. A vet removed one, but decided against operating to take out a possible bullet. The dog initially appeared content indoors, sitting in Cheramie's lap or napping beside her bed. Then while she was out one day, Scrim chewed through a mesh screen, dropped 13 feet to the ground and squeezed through a gap in the fence, trotting away. Murray said Cheramie's four cats probably spooked him. “I wholeheartedly believe the gangster-ass cats were messing with him,” Murray said. Cheramie thinks they may have gotten territorial. Devastated but undeterred, the pair is reassessing where Scrim might fit best — maybe a secure animal sanctuary with big outdoor spaces where other dogs can keep him company. Somewhere, Murray says, “where he can just breathe and be.” Brook is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues. Follow Brook on the social platform X: @jack_brook96If social media and influencer culture have been good for any industry, it would have to be cameras. Platforms like Instagram and TikTok beg users to capture the world for all to see, whether it's through ridiculous stunts, random acts of kindness, scripted skits, or outlandish adventures. At the center of every parkour video and trending challenge post, a camera is there to absorb the moment so it can be replayed for all the world to witness. That sounds like a pretty hefty undertaking, which is why you may tend to see the same camera brands being trusted. Among the more common is Insta360, a relatively new entry in the camera scene behind the revered 8K recordings of the Insta360 X4 . Introduced in 2015, nine years after GoPro came onto the market with a 35mm GoPro Hero, Insta360 rapidly expanded to eventually establish a product base of more than a dozen handheld, miniature, or action cameras. According to the Insta360 website, the goal of the brand was to develop a 360-degree camera that could capture panoramic videos to pull viewers into the action. Today, it continues to improve upon the concept in offices based in Los Angeles, Hong Kong, Berlin, Shenzhen, and Tokyo. Though Insta360 expanded into those territories, none of them are where the company was established. Nor are they where the cameras are manufactured. For those locations, we'll need to look across the Atlantic. Unlike the known practice of some American companies, Insta360 isn't an American-made brand outsourcing its manufacturing to another country. While you'll find local corporations like Apple moving the assembly of products like the iPhone to China, that isn't quite the case for the camera manufacturer. That's because Insta360 is already a Chinese company doing business under the name Arashi Vision, Inc. out of Shenzhen. Before becoming as big as it is today, though, Insta360 was a concept that took shape in a dorm room on the Nanjing University campus. When JK Liu conceived of the idea for the 360-degree camera, panoramic video wasn't common among casual videographers, as the tools were still big and cumbersome. In 2015, after his graduation from Nanjing, Liu went to work on a user-friendly panoramic camera. The result was Insta360, which immediately found a home in Shenzhen, a district known for its thriving tech industry and access to components. Despite its growth after the Insta360 Nano premiered at the Consumer Electronics Show in 2017, the company kept its roots in Shenzen. As of December 2024, JK Liu was still noted as the CEO of Arashi Vision and even earned a spot on Forbes 30 Under 30. Considering all the production it takes on for the United States, it can be reasoned fairly simply that a China-based company would handle its own manufacturing. While not explicitly stated anywhere on the Insta360 website, the country of origin is mentioned on the Amazon listings of some of its cameras, like the tiny but serviceable Insta Go 3 . Per the listing, Insta360 cameras are manufactured out of the company's parent country, China. While Amazon requires all companies to list the country of origin for products, it's not something that is necessarily verified. However, there's no real benefit for Insta360 to lie about China being the originating country. As for the satellite offices outside of Shenzhen and China, they may not manufacture products, but they do serve a consumer-facing purpose. When searching for an Insta360 service center on the official website, most countries are directed to contact service centers in Hong Kong, Germany, California, and Japan. A select few, like the Philippines, are directed to contact a local company that seems unaffiliated with Insta360. For the Philippines, it's Agile Technologies' TekMage, an authorized repair service center located in Manila.

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIacces.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: The CAHtalyst Pediatric study met its primary endpoint, with CRENESSITY significantly decreasing androstenedione levels from baseline to Week 4 versus patients taking placebo who experienced a substantial increase in androstenedione levels. Children taking CRENESSITY were also able to significantly reduce their GC doses at Week 28 while maintaining or improving androgen levels, a key secondary endpoint. Children taking CRENESSITY saw approximately four times greater reduction in androstenedione compared with those taking placebo. Approximately four times greater steroid dose reduction in children taking CRENESSITY was seen compared with those taking placebo. Children taking CRENESSITY saw approximately 12 times greater reduction in 17-hydroxyprogesterone (17-OHP) compared with those taking placebo. Headache, abdominal pain, fatigue, nasal congestion and nosebleed were the most common adverse drug reactions (ADRs) among the pediatric population treated with CRENESSITY. Most side effects were temporary and mild to moderate in severity. Phase 3 CAHtalyst Adult Study: The CAHtalyst Adult study met its primary endpoint with CRENESSITY enabling significant GC dose reductions at Week 24 (while maintaining or improving baseline androstenedione levels) and key secondary endpoint of decreasing androstenedione levels at Week 4. A significantly higher number of patients taking CRENESSITY (63%) achieved a GC dose in the physiologic range while androstenedione was maintained or improved compared with patients taking placebo (18%). Approximately two times greater steroid dose reduction was seen in people taking CRENESSITY compared with those taking placebo. People taking CRENESSITY saw an eight times greater reduction in androstenedione compared with those taking placebo. People taking CRENESSITY saw a 37 times greater reduction in 17-OHP compared with those taking placebo. Fatigue, headache, dizziness, joint pain, back pain, decreased appetite and muscle pain were the most common ADRs in the CRENESSITY treatment group. Most side effects were temporary and mild to moderate in severity. CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 SOURCE Neurocrine Biosciences, Inc.Putin says will carry out more Oreshnik missile tests in combat MOSCOW: Russian President Vladimir Putin said on Friday that Moscow would carry out more tests of the hypersonic Oreshnik ballistic missile in “combat conditions,” a day after firing one on Ukraine. “We will continue these tests, including in combat conditions, depending on the situation and character of the security threats posted to Russia,” Putin said in a televised meeting with military chiefs. The Kremlin boss also ordered the missile, which flies at speeds of Mach 10 -- 10 times the speed of sound -- to be put into serial production. Russia is developing similar advanced systems, he added. “We need to begin serial production. The decision... has in effect been taken,” Putin said, praising the “particular strength of this weapon and its power. “The weapon system that was tested yesterday is another faithful guarantee of Russia ́s territorial integrity and sovereignty,” he added. Putin claimed no other countries in the world had such missile technology. While he conceded other states would soon develop them, he said: “That will be tomorrow, after a year or two. But we have this system now. That ́s important.” His choreographed meeting with the defence minister and those in charge of developing the missile came at the end of a week that has seen the Ukraine conflict escalate rapidly. Putin said the firing of the Oreshnik missile was a direct response to Kyiv ́s forces using US- and UK-supplied missiles on Russian territory for the first time. In an address to the nation on Thursday, Putin said Russia reserved the right to fire missiles at military facilities in countries whose weapons are being used by Ukraine -- specifically the United States and Britain. Meanwhile, Ukraine ́s parliament has cancelled Friday ́s session, lawmakers said, citing the risk of a Russian missile attack on the district of Kyiv where government buildings are located.The move comes after several foreign embassies, including the US representative office, shuttered temporarily over the threat of a strike on Kyiv. “The hour of questions to the government has been cancelled,” Yevgenia Kravchuk, an MP from the ruling party told AFP. “There are signals of an increased risk of attacks on the government district in the coming days.” The cancellation also comes a day after Russian President Vladimir Putin issued a warning to the West by test-firing a new intermediate-range missile at Ukraine.

None

Maryland Sen. Ben Cardin closed an emotional farewell to a 58-year political career that a Senate leader said “put substance over flash.”AP News Summary at 6:44 p.m. EST

Stock market today: Nasdaq hits a record as Wall Street drifts ahead of Federal Reserve's meeting

De'Vondre Campbell's mid-game quitting overshadowed the 49ers' offensive woes